TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing isolated OPCAB.~* Age: 20\~75.~Exclusion Criteria:~* Emergency operation.~* Patients with MR ≥ 2.~* Patients with IDDM.~* Patients with random sugar ≥ 250 mg/dL.~* Patients with serum creatinine ≥ 2.0 mg/dL.~* Patients with acute myocardial infarction within 1 week of surgery

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GIK group (Type: EXPERIMENTAL): None
- Control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ramipril in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with rheumatoid arthritis (4 out of 7 ARA criteria must be fulfilled to establish diagnosis) on stable background therapy for the last three months~* endothelial dysfunction (FMD \< 4%, FMD:Flow-Mediated-Dilatation)~* non-smokers~Exclusion Criteria:~* previous myocardial infarction, coronary intervention or coronary surgery~* previous treatment with statins in the last 6 months~* previous treatment with ACE-inhibitors in the last 6 months~* uncontrolled hypertension SAP/DAP \> 160/90 mmHg (SAP:Systolic Arterial Pressure, DAP:Diastolic Arterial Pressure)~* dyslipidemia (LDL-cholesterol \> 4.9 mmol)~* normal CRP \< 3 mg/l~* overweight BMI \> 35kg/m2~* anaemia (hemoglobin \< 10g/dl)~* kidney disease (creatinine \> 150 umol/l)~* insulin-dependent diabetes mellitus~* congestive heart failure (\> NYHA I)~* AV-Block\>I~* pregnancy~* angio-edema~* malignancy or chronic infection~* drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* use of lopinavir 400mg/ritonavir 100mg bid \> 3months~* HIV-1 RNA \<400cop/mL~* fasting total cholesterol \> 6.2mmol/L~Exclusion Criteria:~* history of sensitivity/idiosyncrasy to the drug or compounds used~* history or current condition that might interfere with absorption,distribution metabolism or excretion~* pregnant or breast-feeding~* serum transaminase levels \>3 times upper limit of normal, creatinine clearance \<60ml/min~* fasting plasma triglycerides level \>8.0 mmol/L~* history of statin-related rhabdomyolysis or inheritable muscle diseases in family history~* clinical symptoms of myopathy or abnormal CK level~* change in antiretroviral medication within the 3 months immediately preceding first dose of rosuvastatin~* use of any statin or fibrate within 6 weeks immediately preceding first dose of rosuvastatin~* concomitant use of medications that interfere with rosuvastatin or lopinavir pharmacokinetics~* active hepatobiliary or hepatic disease~* hypothyroidism~* alcohol abuse~* japanese or chinese patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with Type II-diabetes mellitus on metformin who are planned to be managed with vildagliptin or glimepiride plus metformin at the time of inclusion.~* Symptomatic Coronary Artery Diseases. (\>30 days).~Exclusion Criteria:~* Hepatic impairment.~* Active malignancy.~* Planned surgical intervention.~* Any signs of hypersensitivity or contraindication to study drugs developed.~* Any patient with any signs of active infection or thrombosis at the time of assessment.~* Addition of any antidiabetic medications or insulin during follows up.~* Chronic inflammatory disease (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection).~* Clinically advanced congestive heart failure - New York Heart Association III-IV~* Severe left ventricular dysfunction (LVEF\<30%) with New York Heart Association II or any New York Heart Association class with documented recent heart failure decompensation (\<3 months)~* Severe stable cardiac angina Community Competence Scale III - IV or Unstable angina~* Pregnancy, lactation or child-bearing potential.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vildagliptin / metformin (Type: EXPERIMENTAL): Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
- glimepiride / metformin. (Type: EXPERIMENTAL): Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TrasGEX™: Phase 1 Study in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Signed written informed consent granted prior to initiation of any study-specific procedures;~2. Male or female patients of ≥18 years of age;~3. ERBB2 (HER-2) gene amplification or ERBB2 overexpression~4. Histologically or cytologically confirmed cancer, either locally advanced or metastatic;~5. No anti-tumor therapy of proven benefit available at study enrollment;~6. Life expectancy of \>=3 months;~7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<=2;~8. Male or female patients of child-producing potential must agree to use contraceptive measures or oral contraception during the study and for 28 days after the last dose of TrasGEX™;~9. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of TrasGEX™;~and~Main Exclusion Criteria:~1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks of the first dose of TrasGEX™;~2. Major surgery within four weeks of the first dose of TrasGEX™;~3. Newly diagnosed brain metastases, metastases that have been documented to be stable for \<3 months, or metastases for which systemic corticosteroids are required;~4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as TrasGEX™;~5. History of myocardial infarction within 12 months of the administration of the first dose of TrasGEX™;~6. History of congestive heart failure defined as Class II to IV per New York Heart Association classification within 12 months of the administration of the first dose of TrasGEX™;~7. Left ventricular ejection fraction \<50%;~8. Previous malignancy other than the current diagnosis within 5 years of the first dose of TrasGEX™;~9. Pregnancy or lactation; and~10. Concurrent uncontrolled significant illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TrasGEX (Type: EXPERIMENTAL): A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Between 18 and 45 years old~* Without treatment during the 7 days before inclusion specially no use of antalgic and anti-inflammatory~* Cooperation and understanding enough to conform to the study obligations -Having given free, informed written consent~* Affiliated at system of French social security~* Inscription or acceptation of inscription in the national register of volunteers involved in trials.~Exclusion Criteria:~* Patient with one or many contraindication for the administration of the trial's products,~* Patient that have taken N-acetylcysteine as bronchial thinner during the last 3 days,~* Patient with medical or surgical history judged by the investigator or his representative as being not compatible with the clinical trial~* Patient with disease progression during inclusion,~* Patient with excessive consumption of alcohol, tobacco (+ than 10 cigarette/day), coffee, tea or drinks with caffeine (equivalent to more than 4 cup a day) or any addiction to drugs,~* Patient with a heat pain mean threshold during training higher or equal to 46.5°C,~* Patient who participated in another clinical trial, located in exclusion period or received benefits \> 4500 euros during 12 months before the beginning of trial,~* Patient with cooperation and understanding that do not allow him to follow the trial,~* Patients with minor or under guardianship,~* No affiliation at system of French social security

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- acetaminophen (Type: EXPERIMENTAL): The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine~1. - decrease the antinociceptive effect of acetaminophen in comparison to a group control~2. - and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme
- placebo (Type: PLACEBO_COMPARATOR): 1. - decrease the antinociceptive effect of acetaminophen in comparison to a group control~2. - and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Interstitial Pneumonitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in the study, subjects must meet all of the following criteria:~* Age 18 to 70 years~* No previous therapy with rituximab~* At least 2 pulmonary function tests within past 6 months~* Diagnosis of co-existing IMID and a severe and / or progressive IP characterized by 3 out of the following items:~* Respiratory symptoms consistent with interstitial lung disease~* Diagnosis of usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP) or a mixed form of UIP / NSIP / OP by either of the following:~* Open or video-assisted thoracic surgery (VATS) lung biopsy showing definite or probable UIP / NSIP / OP~* High Resolution Computer Tomography (HRCT) scan showing definite or probable UIP/NSIP/OP/mixed~* Forced Vital Capacity (FVC) \< 50% predicted and/or diffusing capacity of the lung for carbon monoxide (DLCO) \< 40% predicted or worsening of lung function as demonstrated by any one of the following within the past year:~* \> 10% decrease in FVC~* \> 15% decrease in DLCO~* Therapy resistance to 1st (corticosteroids) and 2nd line therapy(cyclophosphamide or azathioprine)~Exclusion Criteria:~A potential subject who meets any of the following criteria will be excluded from participation in this study:~* Residual volume \>120% predicted at screening~* DLCO \<25% of predicted value at screening + resting Oxygen Saturation (SAO2) without external oxygen \<90%~* History of unstable or deteriorating cardiac or neurological disease~* Pregnancy or lactation~* Hematology lower than specified limits (leucocytes)~* Positive HIV, hepatitis B or C serology~* Pre-existing conditions which lead to a life expectancy of less than 6 months~* Receipt of any vaccine, particularly live viral vaccines, within 4 weeks before first rituximab dose~* Hypersensitivity for murine proteins~NOTE:~* Fever (\>37,9 °C) at presentation is reason to delay therapy by 1 week~* Evidence of active infection is reason to postpone rituximab treatment until no further signs of active infection~* Severe renal impairment is not a contraindication for rituximab therapy, however, if patients (might) require dialysis frequently they will be excluded from the study group

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- rituximab (Type: OTHER): single arm study with Zr-89-rituximab immuno PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Confirmed diagnosis of T2DM by standard criteria.~* Treatment with oral anti-diabetic therapy, on stable dose for at least 12 weeks prior to the screening visit. Acceptable background anti-diabetic therapy includes: metformin (≥ 1500 mg) as monotherapy or in combination with SU, TZDs, or glinides~* Age: ≥18 to ≤ 80 years~* HbA1c of ≥ 7.5 and ≤ 11.0%~* Body Mass Index (BMI) ≥22 to ≤45 kg/m2~Exclusion criteria:~* FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)~* Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months~* Any of following within past 6 months: Myocardial infarction, TIA or stroke, coronary artery bypass surgery or percutaneous coronary intervention~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes~* Acute infections which may affect blood glucose control within 4 weeks prior to screening Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (metformin + glimepiride) (Type: EXPERIMENTAL): None
- Placebo (metformin + glimepiride) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Community-based Intervention Among Active Drug Users in Montpellier

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years~* Be an active drug user defined by:~  1. Report current and regular (Last uptake no more than 3 days ago and at least 10 times a month) use of illicit psychoactive substances other than cannabis (heroin, amphetamines, cocaine, MDMA/ecstasy, cathinones) or misused medications (methadone, buprenorphine, opiate drugs, methylphenidate, ketamine) AND~ 2. Positive urine test for a psychoactive substance other than cannabis (Heroin, amphetamines, cocaine, MDMA/ecstasy, cathinones) or a misused medication (methadone, buprenorphine, opiate drugs, methylphenidate, ketamine).~Exclusion Criteria:~* Inability to understand the study~* Be under guardianship, curatorship or future protection mandate~* Lack of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All patients (Type: OTHER): All participants recruited during the RDS survey.
- HCV infected patients (Type: OTHER): HCV-RNA assay (GeneXpert, Cepheid) will be performed to determine if patients have chronic hepatitis C (defined by HCV-RNA\>10 UI/mL)
- Patients with hepatitis C (Type: OTHER): Patients diagnosed with chronic hepatitis C will be prescribed with DAA treatment on research site. After one month they will be referred to conventional health structure for treatment follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: New Technologies to Help Manage ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents of children are eligible to participate if~  1. their child receives ADHD care at one of the pediatric primary care practices that is partnering to conduct this trial~ 2. child being registered on myADHDportal.com to initiate child assessment of ADHD~ 3. child age 6-10 years~ 4. child must not have been previously treated with ADHD medication~ 5. child prescribed ADHD medication within 12 months of enrolling in the study~Exclusion Criteria:~* Unable to read and speak English

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- enhanced myADHDportal.com (Type: EXPERIMENTAL): Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
- treatment as usual standard portal (Type: ACTIVE_COMPARATOR): Standard version of myADHDportal.com web software

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Eligible patients must have a diagnosis of chronic angina, with documented evidence of coronary artery disease or prior myocardial infarction, in addition to other study entry criteria. Prior to entering the study, patients will be required to have had at least two weeks of treatment with amlodipine 10 mg daily, with the discontinuation of all other anti-anginal therapy for the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safe and Healthy Schools

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* school children ages 4-19~* MMSD staff~* have at least one symptom of COVID-19~* have not had a positive COVID-19 test in the past 3 months~* will undergo nasal PCR testing at an MMSD elementary school~Exclusion Criteria:~* received a positive COVID-19 test in the past 3 months~Criteria for inclusion in the final study sample:~* Aim 1. Symptomatic participants with a negative at-school BinaxNOW test and nasal PCR results who complete both the lollipop PCR and at-home BinaxNOW tests within 72 hours will be included in the final study sample.~* Aim 2. Symptomatic participants who provide a lollipop swab that is successfully resulted.~Criteria for exclusion in the final study sample:~* Aim 1~  * Missing nasal PCR result~ * Do not successfully complete an at-home BinaxNOW test within 72 hours of the at-school BinaxNOW test~* Aim 2~  * Missing nasal PCR result~ * Missing lollipop PCR result

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BinaxNOW Test + Lollipop PCR (Type: EXPERIMENTAL): If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing.~If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later.~For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete